Infliximab Therapeutic Mixture

Mixed immunological preparation containing infliximab monoclonal antibodies for autoimmune diseases like Crohn's. HTS 3002.14.0010 for bulk mixed monoclonal products used in biotech manufacturing. Includes polysorbate and histidine buffers.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3003.31.00Higher: 10% vs Free

If organometallic antibiotic mixture

If combined with metal-based antibiotics, may shift to medicaments of 3003.

3504.00.50Higher: 21.5% vs Free

If primarily peptide/protein without immunological claim

Bulk proteins without specific immune function classify under enzymes/peptides.

3002Same rate: Free

If for specific blood antisera products

Traditional antisera without monoclonals use different subheading.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Provide immunogenic profile data; monitor for anti-drug antibody formation risks

Use validated shipping containers for biologics; include stability data at import temps

Confirm not a 'simple vegetable extract' per chapter note 3 to maintain classification

Related Products under HTS 3002.14.00.10

Rituximab Biosimilar Immunological Preparation

A mixed immunological product containing rituximab monoclonal antibodies used for treating non-Hodgkin lymphoma and rheumatoid arthritis. Classified under HTS 3002.14.0010 as it is an immunological product containing monoclonal antibodies, not put up in measured doses or retail packings. It consists of multiple components including the antibody and stabilizers for therapeutic use.

Trastuzumab Emtansine Mixture

Immunological preparation mixing trastuzumab monoclonal antibody with emtansine for HER2-positive breast cancer treatment. Falls under HTS 3002.14.0010 due to monoclonal antibody content in a mixed, non-retail bulk form for hospital use. Includes buffers and stabilizers as mixed components.

Pembrolizumab Bulk Immunological Product

Mixed preparation of pembrolizumab (Keytruda) monoclonal antibody for immunotherapy in melanoma and lung cancer. HTS 3002.14.0010 applies to this bulk mixed form containing the antibody with formulation excipients, not for retail. Used in clinical or manufacturing settings.

Bevacizumab Biosimilar Mixture

Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.

Adalimumab Reference Product Bulk

Bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment. Falls under HTS 3002.14.0010 as mixed immunological product with monoclonal antibodies, supplied for further dilution. Not in measured retail doses.

Nivolumab Immunotherapy Preparation

Mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy. HTS 3002.14.0010 classification for bulk mixed immunological containing monoclonals for clinical trials. Includes sucrose stabilizer and buffer system.